Literature DB >> 19394154

Defining the clinical target volume for bladder cancer radiotherapy treatment planning.

Peter Jenkins1, Salim Anjarwalla, Hugh Gilbert, Richard Kinder.   

Abstract

PURPOSE: There are currently no data for the expansion margin required to define the clinical target volume (CTV) around bladder tumors. This information is particularly relevant when perivesical soft tissue changes are seen on the planning scan. While this appearance may reflect extravesical extension (EVE), it may also be an artifact of previous transurethral resection (TUR). METHODS AND MATERIALS: Eighty patients with muscle-invasive bladder cancer who had undergone radical cystectomy were studied. All patients underwent preoperative TUR and staging computed tomography (CT) scans. The presence and extent of tumor growth beyond the outer bladder wall was measured radiologically and histopathologically.
RESULTS: Forty one (51%) patients had histologically confirmed tumor extension into perivesical fat. The median and mean extensions beyond the outer bladder wall were 1.7 and 3.1 mm, respectively. Thirty five (44%) patients had EVE, as seen on CT scans. The sensitivity and specificity of CT scans for EVE were 56% and 79%, respectively. False-positive results were infrequent and not affected by either the timing or the amount of tissue resected at TUR. CT scans consistently tended to overestimate the extent of EVE. Tumor size and the presence of either lymphovascular invasion or squamoid differentiation predict a greater extent of EVE.
CONCLUSIONS: In patients with radiological evidence of extravesical disease, the CTV should comprise the outer bladder wall plus a 10-mm margin. In patients with no evidence of extravesical disease on CT scans, the CTV should be restricted to the outer bladder wall plus a 6-mm margin. These recommendations would encompass microscopic disease extension in 90% of cases.

Entities:  

Mesh:

Year:  2009        PMID: 19394154     DOI: 10.1016/j.ijrobp.2009.01.063

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

Review 1.  Image-guided radiation therapy for muscle-invasive bladder cancer.

Authors:  Juliette Thariat; Shafak Aluwini; Qiong Pan; Mickael Caullery; Pierre-Yves Marcy; Martin Housset; Jean-Leon Lagrange
Journal:  Nat Rev Urol       Date:  2011-11-08       Impact factor: 14.432

2.  Impact of variant histology on disease aggressiveness and outcome after nephroureterectomy in Japanese patients with upper tract urothelial carcinoma.

Authors:  Shigeru Sakano; Hideyasu Matsuyama; Yoriaki Kamiryo; Shigeaki Hayashida; Norio Yamamoto; Yoshitaka Kaneda; Takahito Nasu; Yoshikazu Baba; Tomoyuki Shimabukuro; Akinobu Suga; Mitsutaka Yamamoto; Akihiko Aoki; Kimio Takai; Satoru Yoshihiro; Kazuo Oba
Journal:  Int J Clin Oncol       Date:  2014-06-27       Impact factor: 3.402

3.  Prospective evaluation of microscopic extension using whole-mount preparation in patients with hepatocellular carcinoma: Definition of clinical target volume for radiotherapy.

Authors:  Weihu Wang; Xiaoli Feng; Tao Zhang; Jing Jin; Shulian Wang; Yueping Liu; Yongwen Song; Xinfan Liu; Zihao Yu; Yexiong Li
Journal:  Radiat Oncol       Date:  2010-08-23       Impact factor: 3.481

4.  Method of computing direction-dependent margins for the development of consensus contouring guidelines.

Authors:  Liam S P Lawrence; Lee C L Chin; Rachel W Chan; Timothy K Nguyen; Arjun Sahgal; Chia-Lin Tseng; Angus Z Lau
Journal:  Radiat Oncol       Date:  2021-04-13       Impact factor: 3.481

5.  Editorial Comment: Endoclips as novel fiducial markers in trimodality bladder preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient out-comes.

Authors:  Rodolfo Borges Dos Reis; Valdair Francisco Muglia; Antônio Antunes Rodrigues; Gustavo Viani
Journal:  Int Braz J Urol       Date:  2021 Jan-Feb       Impact factor: 1.541

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.